Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808337 · ClinicalTrials.gov registry record · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
A Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 12
- Study locations
NCT03808337 is a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 145 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The trial reports 12 study locations across 6 states.
The verdict
NCT03808337, a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiotherapy/SBRT
- DRUG Systemic Therapy/Standard of Care
Study Locations (12)
New York
- Memorial Sloan Kettering Cancer Center @ Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Connecticut
- Hartford Healthcare - Hartford
- WCHN Norwalk Hospital - Data Collection - Norwalk
California
- Natera, Inc. (Data and Specimen Analysis Only) - San Carlos
Florida
- Baptist Alliance - McI - Miami
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808337
The ClinicalTrials.gov registry entry for NCT03808337 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiotherapy/SBRT is the first listed.
NCT03808337 reports 12 study locations spanning 6 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03808337 about?
NCT03808337 is a clinical study titled "Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease". This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
What is the current status of trial NCT03808337?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2019-01-16. Estimated completion is 2027-01.
What conditions does trial NCT03808337 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03808337?
The interventions under investigation include: Stereotactic Body Radiotherapy/SBRT (RADIATION), Systemic Therapy/Standard of Care (DRUG).
Who is sponsoring clinical trial NCT03808337?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03808337 being conducted?
This trial has 12 study locations across California, Connecticut, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.